-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $219

Benzinga·12/10/2025 16:47:15
Listen to the news
Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $147 to $219.